ALS Association’s Drug Company Working Group Meets To Discuss ALS Developments

A few weeks ago, at the 65th Annual Meeting of the American Academy of Neurology held in San Diego, California, the ALS Association’s Drug Company Working Group met to discuss several important developments in ALS clinical trials and research. Click on the link below to read short summaries about the important findings that came out of the Dexpramipexole trial, the developments around the Phase II Tirasemtiv trial, as well as the recent discoveries around biomarkers — including the use of an imaging biomarker to monitor a levels of the EAAT2 glutamate transporter and biomarker that could be used to monitor ALS-associated changes in the immune system.

Click here to read more.

Share this: